Pharsight

Trintellix generic

Trintellix is an anti-depressive drug owned by Takeda Pharms Usa. The active ingredient in Trintellix is vortioxetine hydrobromide. This drug was first authorized for market use on September 30, 2013, and comes in a tablet form that's taken orally.

When will Trintellix generic be available?

The Trintellix generic version will be available after September 21, 2032. This generic availability date is influenced by the patent US9278096, titled 'Therapeutic uses of compounds having combined SERT, 5-HT3, and 5-HT1A activity', which will expire on September 21, 2032.

Trintellix uses

Trintellix can be used for the treatment of major depressive disorder. It is also used to improve processing speed, an aspect of cognitive function, and to treat affective disorders like depression. Trintellix is further used for the treatment of treatment-emergent sexual dysfunction (TESD) that's induced by prior serotonin reuptake inhibitor treatment.

Trintellix patent expiration

Trintellix holds 21 patents, of which 1 has already expired. The patent details affecting the availability of Trintellix generic is US9278096, which will expire on September 21, 2032. Below are the details of the patent:

EPO Oppostions filed on Trintellix

Trintellix dosage

Want to ask something?